Synergy Innovation "Saliva and Antigen Specimen Collection Kit Approved by US FDA"

[Asia Economy Reporter Hyunseok Yoo] Synergy Innovation announced on the 16th that it has obtained U.S. FDA product approval for saliva and antigen (rapid diagnostic kit) specimen collection kits.

Through this FDA approval, the company plans to expand its product lineup across all specimen collection kits and actively target overseas markets.

The saliva and antigen specimen collection kits feature significantly improved virus preservation and survival rates compared to the traditional method of collecting specimens with swabs from the nose and throat. As the novel coronavirus infection (COVID-19) is resurging worldwide, demand for saliva and antigen specimen collection kits overseas is steadily increasing, and it is expected that export opportunities to foreign markets will open in earnest.

A company official stated, “By consecutively obtaining U.S. FDA product approvals, we have secured trust in product quality and laid the groundwork for additional exports of specimen collection kits. As demand for saliva and antigen specimen collection kit products is increasing mainly in North America and Japan, we plan to actively target overseas markets.”

Meanwhile, Synergy Innovation has obtained European CE certification and U.S. FDA product approval for specimen collection kits and is steadily expanding production facilities to meet overseas demand.

This content was produced with the assistance of AI translation services.